Strengthening and diversifying our portfolio through multiple partnerships.

Uni-Bio Science proactively assesses opportunities to broaden its product offering through in-licensing innovative treatments from global pharmaceutical partners seeking to leverage our broad development, manufacturing, sales and marketing and infrastructure. Uni-Bio Science evaluates potential candidates that are indicated for diseases prevalent in the Chinese population and are at all stages of development and commercialisation, which complement its portfolio.

For more information on our partnering strategy please contact our Head of Business Development via [email protected]

Uni-Bio Science is the partner of choice in China for global pharmaceutical companies

Uni-Bio Science's partners include :

In November 2015, Uni-Bio Science acquired exclusive global rights to manufacture and commercialise Mitiglinide, a new oral antidiabetic agent, from Jiangsu Hansoh Pharmaceutical Co. Ltd.

In September 2014, Uni-Bio Science signed a cooperative partnership agreement with Samil Pharmaceuticals. Uni-Bio Science is the exclusive distributor for Samil's four drug products (Rhinex, Ocucyclo, Lantanoprost and Allenol) in mainland China, Hong Kong and Macau for 8 years, with an option to extend for a further 4 years.